Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
Status: Enrolling
Updated:  2/25/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
Status: Enrolling
Updated: 2/25/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated:  2/25/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated: 2/25/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated:  2/25/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated: 2/25/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting
Status: Enrolling
Updated:  2/25/2016
Kaiser Permanente Northwest
mi
from
Portland, OR
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting
Status: Enrolling
Updated: 2/25/2016
Kaiser Permanente Northwest
mi
from
Portland, OR
Click here to add this to my saved trials
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
A Phase II Trial of Celecoxib in Patients With IPMN
Status: Enrolling
Updated:  2/26/2016
Indiana University Hospital
mi
from
Indianapolis, IN
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
A Phase II Trial of Celecoxib in Patients With IPMN
Status: Enrolling
Updated: 2/26/2016
Indiana University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors
Status: Enrolling
Updated:  2/26/2016
Indiana Univeristy Cancer Center
mi
from
Indianapolis, IN
Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors
Status: Enrolling
Updated: 2/26/2016
Indiana Univeristy Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors
Status: Enrolling
Updated:  2/26/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors
Status: Enrolling
Updated: 2/26/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  2/26/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 2/26/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center
mi
from
Fullerton, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Antelope Valley Cancer Center
mi
from
Lancaster, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Antelope Valley Cancer Center
mi
from
Lancaster, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Pacific Shores Medical Group
mi
from
Long Beach, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Pacific Shores Medical Group
mi
from
Long Beach, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Translational Oncology Research International (TORI) Network
mi
from
Los Angeles, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Translational Oncology Research International (TORI) Network
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Cancer Care Associates Medical Group, Inc.
mi
from
Redondo Beach, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Cancer Care Associates Medical Group, Inc.
mi
from
Redondo Beach, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
TORI REDONDO BEACH (Cancer Care Associates Medical Group, Inc.)
mi
from
Redondo Beach, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
TORI REDONDO BEACH (Cancer Care Associates Medical Group, Inc.)
mi
from
Redondo Beach, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Santa Barbara Hematology Oncology Medical Group, Inc.
mi
from
Santa Barbara, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Santa Barbara Hematology Oncology Medical Group, Inc.
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Sansum Medical Clinic
mi
from
Santa Barbara, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Sansum Medical Clinic
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Central Coast Medical Oncology Corporation
mi
from
Santa Maria, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Central Coast Medical Oncology Corporation
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Trivalley Oncology Hematology
mi
from
Westlake Village, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Trivalley Oncology Hematology
mi
from
Westlake Village, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
North Valley Hematology-Oncology Medical Group
mi
from
Northridge, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
North Valley Hematology-Oncology Medical Group
mi
from
Northridge, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Suburban Hematology/Oncology Associates, Pc
mi
from
Lawrenceville, GA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Suburban Hematology/Oncology Associates, Pc
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Multi-site Decision Impact Study for Decipher
ASSESSing the Impact of Decipher on Practice Decision Making in Prostate Cancer After Surgery
Status: Enrolling
Updated:  2/26/2016
Cedar Associates LLC
mi
from
Menlo Park, CA
Multi-site Decision Impact Study for Decipher
ASSESSing the Impact of Decipher on Practice Decision Making in Prostate Cancer After Surgery
Status: Enrolling
Updated: 2/26/2016
Cedar Associates LLC
mi
from
Menlo Park, CA
Click here to add this to my saved trials
Multi-site Decision Impact Study for Decipher
ASSESSing the Impact of Decipher on Practice Decision Making in Prostate Cancer After Surgery
Status: Enrolling
Updated:  2/26/2016
Florida Hospital
mi
from
Celebration, FL
Multi-site Decision Impact Study for Decipher
ASSESSing the Impact of Decipher on Practice Decision Making in Prostate Cancer After Surgery
Status: Enrolling
Updated: 2/26/2016
Florida Hospital
mi
from
Celebration, FL
Click here to add this to my saved trials
Multi-site Decision Impact Study for Decipher
ASSESSing the Impact of Decipher on Practice Decision Making in Prostate Cancer After Surgery
Status: Enrolling
Updated:  2/26/2016
Columbia University
mi
from
New York, NY
Multi-site Decision Impact Study for Decipher
ASSESSing the Impact of Decipher on Practice Decision Making in Prostate Cancer After Surgery
Status: Enrolling
Updated: 2/26/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma
Status: Enrolling
Updated:  2/26/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma
Status: Enrolling
Updated: 2/26/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Virginia K. Crosson Cancer Center
mi
from
Fullerton, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Virginia K. Crosson Cancer Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Pacific Shores Medical Group
mi
from
Long Beach, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Pacific Shores Medical Group
mi
from
Long Beach, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
North Valley Hematology-Oncology Medical Group
mi
from
Northridge, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
North Valley Hematology-Oncology Medical Group
mi
from
Northridge, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Cancer Care Associates Medical Group, Inc.
mi
from
Redondo Beach, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Cancer Care Associates Medical Group, Inc.
mi
from
Redondo Beach, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Sansum- Santa Barbara medical foundation Clinic
mi
from
Santa Barbara, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Sansum- Santa Barbara medical foundation Clinic
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Santa Barbara Hematology Oncology Medical Group, Inc.
mi
from
Santa Barbara, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Santa Barbara Hematology Oncology Medical Group, Inc.
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Central Coast Medical Oncology Corporation
mi
from
Santa Maria, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Central Coast Medical Oncology Corporation
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
San Diego Cancer Center
mi
from
Vista, CA
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
San Diego Cancer Center
mi
from
Vista, CA
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Cancer Institute Of Florida
mi
from
Orlando, FL
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Cancer Institute Of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated:  2/26/2016
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Status: Enrolling
Updated: 2/26/2016
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
Phase I Study of Gemcitabine With Novel RAF Kinase-Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (BAY 43-9006) and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  2/26/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
Phase I Study of Gemcitabine With Novel RAF Kinase-Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (BAY 43-9006) and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 2/26/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials